Therapeutic effect of glucocorticoid on experimental crescentic glomerulonephritis

Journal of Laboratory and Clinical Medicine

Volumn 134, Issue 4, 1999, Pages 410-418

  Yamamoto Shuda, Yoko ^a,b   Nakayama, Kenji ^a,b   Saito, Takao ^a,b   Natori, Yasuhiro ^a,b  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033214262     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(99)90157-9     Document Type: Article

References (28)

1. 1. Glassock RJ, Cohen AH, Adler SG. Primary glomerular diseases. In: Brenner BM, editor. The kidney. 5th ed. Philadelphia: WB Saunders Co; 1996. p. 1392-497.
2. 2. Bolton WK, Couser WG. Intravenous pulse methylprednisolone therapy of acute crescentic rapidly progressive glumerulonephritis. Am J Med 1979;66:495-502.
3. 3. Bolton WK. Rapidly progressive glomerulonephritis. Semin Nephrol 1996;16:517-26.
4. 4. Atkins RC, Nikolic-Paterson DJ, Song Q, Lan HY. Modulators of crescentic glomerulonephritis. J Am Soc Nephrol 1996;7:2271-8.
5. 5. Wiggins RC, Holzman LB, Legault DJ. Glomerular inflammation and crescent formation. In: Neilson EG, Couser WG, editors. Immunologic renal diseases. Philadelphia: Lippincott-Raven; 1997. p. 669-82.
6. 6. Kawasaki K, Yaoita E, Yamamoto T, Kihara I. Depletion of CD8 positive cells in nephrotoxic serum nephritis of WKY rats. Kidney Int 1992;41:1517-26.
7. 7. Moura A, Mendrick DL, Rennke HG. The primary role of monocytes/macrophages in crescentic glomerulonephritis [abstract]. J Am Soc Nephrol 1992;3:605.
8. 8. Huang XR, Holdsworth SR, Tipping PG. Evidence for delayed-type hypersensitivity mechanisms in glomerular crescent formation. Kidney Int 1994;46:69-78.
9. 9. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993;119: 1198-208.
10. 10. Kobayashi Y, Shigematsu H, Masaki Y, Tateno S, Hiki Y. Effect of methylprednisolone on progressive Masugi nephritis in the rabbit. I. Suppression of antibody production and crescent formation. Virchows Arch B 1980;35:45-61.
11. 11. Holdsworth SR, Bellomo R Differential effects of steroids on leukocyte-mediated glomerulonephritis in the rabbit. Kidney Int 1984;26:162-9.
12. 12. Sado Y, Naito I, Akita M, Okigaki T. Strain specific responses of inbred rats on the severity of experimental autoimmune glomerulonephritis. J Clin Lab Immunol 1986;19:193-9.
13. 13. Shimizu A, Masuda Y, Kitamura H, Ishizaki M, Sugisaki Y, Yamanaka N. Apoptosis in progressive crescentic glomerulonephritis. Lab Invest 1996;74:941-51.
14. 14. Sekiguchi M, Natori Yu, Iyonaga K, Takeya M, Natori Y. Expression of monocyte chemoattractant protein-1 in experimental crescentic glomerulonephritis in rats. J Lab Clin Med 1997;129:239-44.
15. 15. Wada T, Yokoyama H, Furuichi K, Kobayashi KI, Harada K, Naruto M, et al. Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1). FASEB J 1996;10:1418-25.
16. 16. Fujinaka H, Yamamoto T, Takeya M, Feng LL, Kawasaki K, Yaoita E, et al. Suppression of anti-glomerular basement membrane nephritis by administration of anti-monocyte chemoattractant protein-1 antibody in WKY rats. J Am Soc Nephrol 1997;8:1174-8.
17. 17. Natori Y, Natori Yu, Nishimura T, Yamabe H, Iyonaga K, Takeya M, et al. Production of monocyte chemoattractant protein-1 by cultured glomerular epithelial cells: inhibition by dexamethasone. Exp Nephrol 1997;5:318-22.
18. 18. Natori Yu, Ou ZL, Yamamoto-Shuda Y, Natori Y. Expression of lymphotactin mRNA in experimental crescentic glomerulonephritis. Clin Exp Immunol 1998;113:265-8.
19. 19. Schimmer BP, Parker KL. Adrenocorticotropic hormone. Adrenocortical steroids and their synthetic analogs: inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman JG, Limbird LE, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996. p. 1459-85.
20. 20. Saito T, Atkins RC. Contribution of mononuclear leucocytes to the progression of experimental focal glomerular sclerosis. Kidney Int 1990;37:1076-83.
21. 21. DiDonato JA, Saatcioglu F, Karin M. Molecular mechanisms of immunosuppression and anti-inflammatory activities by glucocorticoids. Am J Respir Crit Care Med 1996;154: S11-5.
22. 22. Martin T, Cardarelli PM, Parry GC, Felts KA, Cobb RR. Cytokine induction of monocyte chemoattractant protein-1 gene expression in human endothelial cells depends on the cooperative action of NF-kappa B and AP-I. Eur J Immunol 1997;27:1091-7.
23. 23. Sakurai H, Shigemori N, Hisada Y, Ishizuka T, Kawashima K, Sugita T. Suppression of NF-kappa B and AP-1 activation by glucocorticoids in experimental glomerulonephritis in rats: molecular mechanisms of anti-nephritic action. Biochim Biophys Acta 1997;1362:252-62.
24. 24. Seto M, Kim S, Yoshifusa H, Nakamura Y, Masuda T, Hamaguchi A, et al. Effects of prednisolone on glomerular signal transduction cascades in experimental glomerulonephritis. J Am Soc Nephrol 1998;9:1367-76.
25. 25. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
26. 26. Natori Yu, Sekiguchi M, Ou ZL, Natori Y. Expression of mRNA of CC chemokines in experimental crescentic glomerulonephritis. Clin Exp Immunol 1997;109:143-8.
27. 27. Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med 1976;84:304-15.
28. 28. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980;284:555-6.